Cowen & Co. Keeps Their Buy Rating on Agios Pharma (AGIO)

By Austin Angelo

In a report released today, Chris Shibutani from Cowen & Co. reiterated a Buy rating on Agios Pharma (AGIOResearch Report). The company’s shares closed last Monday at $47.25.

According to, Shibutani is a 4-star analyst with an average return of 6.5% and a 43.8% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Pieris Pharmaceuticals, and Syndax Pharmaceuticals.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $62.43, implying a 33.5% upside from current levels. In a report issued on January 2, Guggenheim also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $68.94 and a one-year low of $28.36. Currently, Agios Pharma has an average volume of 872.4K.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.